Lecanemab – Updated clinical data indicate a modest clinical effect on the disease, with a moderate rate of serious adverse events.
November 30, 2022 - Lecanemab, a monoclonal antibody, clears amyloid and being studied to determine ability to slow the progression of cognitive decline.
Download PDF
